Jasper Therapeutics, Inc. (JSPR)
| Market Cap | 26.03M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -75.80M |
| Shares Out | 28.00M |
| EPS (ttm) | -3.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 181,015 |
| Open | 0.900 |
| Previous Close | 0.930 |
| Day's Range | 0.900 - 0.988 |
| 52-Week Range | 0.623 - 7.190 |
| Beta | 3.20 |
| Analysts | Buy |
| Price Target | 15.50 (+1,567.2%) |
| Earnings Date | May 12, 2026 |
About JSPR
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for JSPR stock is "Buy." The 12-month stock price target is $15.5, which is an increase of 1,567.20% from the latest price.
News
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibo...
Jasper Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Briquilimab showed rapid, deep disease control in urticaria and asthma studies, with a favorable safety profile and differentiated mechanism. Phase II-B/III trials in CSU and CIndU are planned, with dose selection focused on balancing efficacy and safety. Equity financing is likely for upcoming studies.
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod...
Jasper Therapeutics Transcript: Study Result
Updated BEACON and open-label extension data show briquilimab delivers rapid, deep, and durable disease control in CSU and CIndU, with a favorable safety profile and low incidence of adverse events. Results support advancing to a phase 2b study in the second half of 2026.
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
Thomas Wiggans appointed Executive Chairperson Jasper to host an investor webinar on January 8 th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension study ...
Jasper Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Briquilimab clinical programs in CSU and asthma advanced, with new data revealing misdiagnosis in some CSU patients and strong efficacy signals in asthma. Enhanced screening and trial designs are in place, with major data and development milestones expected in early 2024.
Jasper Therapeutics Transcript: Study Result
Unexpected lack of efficacy in BEACON trial U.S. cohorts was attributed to misdiagnosis, not drug failure, with robust safety and efficacy confirmed in properly diagnosed CSU patients. ATESIAN study data showed strong proof of concept for briquilimab in asthma, supporting further development.
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, ...
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Driven Brands Holdings, In...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Jasper to Contact Him Directly to Discuss Their Options If you purchased or acquired ...
Jasper Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
No drug quality issues were found after anomalous patient responses; focus shifted to patient selection and site conduct. New enrollment and stricter criteria are in place, with major data updates from CSU, asthma, and Sindhu studies expected in early Q1 next year.
Jasper Therapeutics Transcript: Stifel 2025 Healthcare Conference
Briquilimab, a mast cell-depleting antibody, shows promising efficacy and safety in urticaria trials, with key data updates and investigation results expected in Q4 and early Q1. Phase IIb in CSU is planned for mid-2026, and the company has cash runway into Q3 2025.
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired ...
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired ...
Jasper Therapeutics to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired ...
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. (JSPR)
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of ...
Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
REDWOOD CITY, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel anti...
Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
REDWOOD CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel anti...
Jasper Therapeutics Transcript: Cantor Global Healthcare Conference 2025
Briquilimab, a KIT-targeting antibody, shows strong efficacy and safety in urticaria trials, with 180 mg every eight weeks providing rapid, sustained symptom relief and outperforming competitors. Ongoing investigations address a confounding drug lot, with expanded data and phase 2b plans expected by year-end.
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibod...
JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $JSPR--JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.